Risk Factors for Treatment-Related Death Associated with Chemotherapy and Thoracic Radiotherapy for Lung Cancer-Reference-Cited by-同舟云学术

Risk Factors for Treatment-Related Death Associated with Chemotherapy and Thoracic Radiotherapy for Lung Cancer

Published:2012-01 Issue:1 Volume:7 Page:177-182
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Minami-Shimmyo Yuko,Ohe Yuichiro,Yamamoto Seiichiro,Sumi Minako,Nokihara Hiroshi,Horinouchi Hidehito,Yamamoto Noboru,Sekine Ikuo,Kubota Kaoru,Tamura Tomohide

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer;Ohe;Eur J Cancer,2001

2. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer;Morittu;Br J Cancer,1989

3. Predicting septic complications of chemotherapy:an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis;Radford;Eur J Cancer,1992

5. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer;Sekine;Cancer Sci,2004

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of Nomograms for Predicting Pneumonia in Patients with COVID-19 and Lung Cancer;Journal of Inflammation Research;2024-06

2. Incidence and appropriate management of drug‐induced interstitial lung disease in Japanese patients with unresectable pancreatic cancer: A multicenter retrospective study;Asia-Pacific Journal of Clinical Oncology;2022-12-07

3. Diagnostic value and safety of endobronchial ultrasonography with a guide sheath transbronchial biopsy for diagnosing peripheral pulmonary lesions in patients with interstitial lung disease;Journal of Thoracic Disease;2022-11

4. Comparison of Pneumonitis Rates and Severity in Patients With Lung Cancer Treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy;Cureus;2022-06-05

5. 30- und 90-Tage-Letalität bei Patienten mit Lungenkarzinom im Stadium IV in Abhängigkeit der Primärtherapie;TumorDiagnostik & Therapie;2022-06